Successful maintenance of molecular remission in chronic myelogenous leukaemia during pregnancy with transition from imatinib to pegylated interferon.
Department of Cancer Services, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
M
M
Ellis
A K
AK
Mills
D000328:Adult; D057915:Drug Substitution; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate / Q000008:administration & dosage*; D007231:Infant, Newborn; D016898:Interferon-alpha / Q000008:administration & dosage*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000188:drug therapy*; D011092:Polyethylene Glycols / Q000008:administration & dosage*; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000175:diagnosis / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000008:administration & dosage; D012074:Remission Induction / Q000379:methods; D016896:Treatment Outcome
D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D000068877:Imatinib Mesylate; C100416:peginterferon alfa-2a